|
시장보고서
상품코드
1789437
세계의 시클로스포린 약제 시장 : 용도별, 제형별, 유형별, 성별, 연령층별, 최종사용자별, 지역별Cyclosporine Drug Market, By Application, By Formulation, By Type, By Gender, By Age Group, By End User, By Geography |
||||||
시클로스포린 약제 시장은 2025년에는 43억 7,000만 달러, 2032년에는 63억 3,000만 달러에 이르고, 2025-2032년 연평균 복합 성장률(CAGR)은 5.4%를 보일 것으로 예측됩니다.
| 보고서 범위 | 보고서 상세 | ||
|---|---|---|---|
| 기준 연도 | 2024년 | 2025년 시장 규모 | 43억 7,000만 달러 |
| 실적 데이터 | 2020-2024년 | 예측 기간 | 2025-2032년 |
| 예측 기간 : 2025-2032년 | 5.40% | 2032년 금액 예측 | 63억 3,000만 달러 |
세계 사이클로스포린 의약품 시장은 1970년대 발견 이후 이식 의료 및 자가면역 질환 관리에 혁명을 가져온 강력한 칼시뉴린 억제제 제제를 포함한 면역억제제 치료의 중요한 부문입니다. 사이클로스포린은 Tolypocladium inflatum이라는 곰팡이에서 유래한 고리형 폴리펩타이드로 T세포의 활성화와 증식을 선택적으로 억제하여 기능하며, 이식 환자의 장기 거부반응 예방과 류마티스 관절염, 건선, 염증성 장질환 등 다양한 자가면역질환 치료에 필수적인 역할을 합니다. 필수적인 역할을 하고 있습니다. 이 시장에는 경구용 캡슐제, 경구용액제, 정맥주사제 등 여러 제형이 있으며, 치료 농도가 다른 브랜드 제품과 제네릭 제품이 모두 판매되고 있습니다. 전 세계 의료 시스템이 이식 수술을 발전시키고 자가면역질환의 치료 옵션을 계속 확대하는 가운데, 사이클로스포린 약물 시장은 새로운 면역억제제의 등장에도 불구하고 그 중요성을 유지하고 있습니다. 투여 요법의 최적화, 생체이용률 향상을 위한 제형 개선, 부작용을 최소화하면서 치료 효과를 극대화하는 병용 요법에 대한 지속적인 연구로 인해 사이클로스포린은 현대 면역억제제 치료 프로토콜의 핵심 치료제로 자리매김하고 있습니다.
시장 역학
세계 사이클로스포린 의약품 시장은 자가면역질환의 유병률 증가, 전 세계 장기 이식 증가, 의료 전문가와 환자의 면역억제요법에 대한 인식 증가 등 몇 가지 주요 촉진요인에 힘입어 성장하고 있습니다. 자가면역질환 및 이식이 필요한 장기부전에 취약한 노년층의 확대는 이식 수술 기술의 발전과 환자 생존율 향상과 함께 장기적인 면역억제요법에 대한 지속적인 수요를 촉진하며 시장 성장에 큰 기여를 하고 있습니다. 또한 장기 이식을 필요로 하는 당뇨병, 심혈관 질환 등 만성질환의 발생률이 증가하고 있는 것도 시장 확대를 더욱 부추기고 있습니다. 그러나 시장에는 안전성 프로파일이 우수한 대체 면역억제제의 가용성, 의약품 승인 및 모니터링에 대한 엄격한 규제 요건, 신흥 시장에서의 사용을 제한할 수 있는 고가의 사이클로스포린 치료 비용 등 여러 가지 제약 요인이 존재합니다. 또한, 사이클로스포린은 치료 범위가 좁고 잦은 약물 모니터링이 필요하기 때문에 의료진과 환자에게 더 많은 어려움을 주는 반면, 신독성, 간독성, 감염 위험 증가 등의 부작용 가능성으로 인해 일부 환자군에서는 사용이 제한될 수 있습니다. 생체이용률 향상과 부작용을 줄인 신규 사이클로스포린 제제 개발, 헬스케어 인프라가 구축되고 있는 시장 진출, 희귀 자가면역질환 치료 적용 가능성 등으로 큰 비즈니스 기회가 창출되고 있습니다. 맞춤의료와 약리유전체학에 대한 관심이 높아지면서 사이클로스포린의 투여 전략을 최적화할 수 있는 기회를 제공하고 있으며, 병용요법 및 새로운 치료 적응증에 대한 지속적인 연구는 시장의 잠재적 범위와 임상적 유용성을 계속 확장하고 있습니다.
본 조사의 주요 특징
- 세계의 사이클로스포린(Cyclosporin) 의약품 시장을 상세하게 분석했으며, 2024년을 기준 연도로 하여 예측 기간(2025-2032년) 시장 규모(10억 달러)와 연평균 성장률(CAGR)에 대해 조사 분석하여 전해드립니다.
- 또한, 다양한 부문에 걸친 잠재적 수익 기회를 밝히고, 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
- 또한 시장 성장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업의 경쟁 전략 등에 대한 중요한 고찰을 제공합니다.
- 이 보고서는 기업 하이라이트, 제품 포트폴리오, 주요 하이라이트, 재무 성과, 전략 등의 매개 변수를 기반으로 세계 사이클로스포린 의약품 시장의 주요 기업을 프로파일링합니다.
- 이 보고서의 통찰력을 통해 마케팅 담당자와 기업 경영진은 향후 제품 출시, 유형화, 시장 확대, 마케팅 전술에 대한 정보에 입각한 의사결정을 내릴 수 있습니다.
- 세계 사이클로스포린 의약품 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 시장 진출기업, 재무 분석가 등 이 산업의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 세계 사이클로스포린 의약품 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 용이하게 할 수 있습니다.
목차
제1장 조사 목적과 전제조건
- 조사 목적
- 전제조건
- 약어
제2장 시장 전망
- 보고서 설명
- 시장 정의와 범위
- 주요 요약
제3장 시장 역학, 규제, 동향 분석
- 시장 역학
- 성장 촉진요인
- 성장 억제요인
- 기회
- 영향 분석
- 규제 시나리오
- 제품 발매/승인
- PEST 분석
- Porter's Five Forces 분석
- 인수합병(M&A) 시나리오
- 산업 동향
제4장 세계의 시클로스포린 약제 시장, 용도별, 2020-2032년
- 서론
- 장기이식 거부반응 예방
- 자가면역질환
- 안질환
- 피부질환
- 기타
제5장 세계의 시클로스포린 약제 시장, 제형별, 2020-2032년
- 서론
- 캡슐
- 정제
- 경구 용액
- 정맥내 용액
- 국소 용액
- 안약
제6장 세계의 시클로스포린 약제 시장, 유형별, 2020-2032년
- 서론
- 브랜드
- 제네릭
제7장 세계의 시클로스포린 약제 시장, 성별, 2020-2032년
- 서론
- 남성
- 여성
제8장 세계의 시클로스포린 약제 시장, 연령층별, 2020-2032년
- 서론
- 소아
- 성인
- 고령자
제9장 세계의 시클로스포린 약제 시장, 최종사용자별, 2020-2032년
- 서론
- 병원
- 전문 클리닉
- 외래수술센터(ASC) 또는 이식센터
- 홈케어
- 학술연구기관
- 기타(전문 약국)
제10장 세계의 시클로스포린 약제 시장, 지역별, 2020-2032년
- 서론
- 북미
- 미국
- 캐나다
- 라틴아메리카
- 브라질
- 아르헨티나
- 멕시코
- 기타 라틴아메리카
- 유럽
- 독일
- 영국
- 스페인
- 프랑스
- 이탈리아
- 러시아
- 기타 유럽
- 아시아태평양
- 중국
- 인도
- 일본
- 호주
- 한국
- ASEAN 국가
- 기타 아시아태평양
- 중동
- GCC 국가
- 이스라엘
- 기타 중동
- 아프리카
- 남아프리카
- 북아프리카
- 중앙아프리카
제11장 경쟁 구도
- Novartis AG
- Teva Pharmaceutical
- Sun Pharmaceuticals
- Mylan(Viatris)
- Hikma Pharmaceuticals
- Glenmark Pharmaceuticals
- Zydus Lifesciences
- Lupin Limited
- Cipla Ltd
- Santen Pharmaceutical
- Amneal Pharmaceuticals
- Endo International
- Strides Pharma
- Panacea BIoTec
제12장 애널리스트 추천 사항
- 기회
- COP(Coherent Opportunity Map)
제13장 참고 문헌과 조사 방법
- 참고 문헌
- 조사 방법
- 출판사에 대해
Cyclosporine Drug Market is estimated to be valued at USD 4.37 Bn in 2025 and is expected to reach USD 6.33 Bn by 2032, growing at a compound annual growth rate (CAGR) of 5.4% from 2025 to 2032.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2024 | Market Size in 2025: | USD 4.37 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: | 5.40% | 2032 Value Projection: | USD 6.33 Bn |
The global cyclosporine drug market represents a critical segment within the immunosuppressive therapeutics landscape, encompassing pharmaceutical formulations of this potent calcineurin inhibitor that has revolutionized transplant medicine and autoimmune disease management since its discovery in the 1970s. Cyclosporine, a cyclic polypeptide derived from the fungus Tolypocladium inflatum, functions by selectively inhibiting T-cell activation and proliferation, making it indispensable for preventing organ rejection in transplant recipients and treating various autoimmune conditions including rheumatoid arthritis, psoriasis, and inflammatory bowel disease. The market encompasses multiple formulations including oral capsules, oral solutions, and intravenous preparations, with both branded and generic versions available across different therapeutic concentrations. As healthcare systems worldwide continue to advance transplantation procedures and expand treatment options for autoimmune disorders, the cyclosporine drug market maintains its significance despite the emergence of newer immunosuppressive agents. The market's evolution is characterized by ongoing research into optimized dosing regimens, improved formulations with enhanced bioavailability, and combination therapies that maximize therapeutic efficacy while minimizing adverse effects, positioning cyclosporine as a cornerstone therapy in modern immunosuppressive treatment protocols.
Market Dynamics:
The global cyclosporine drug market is propelled by several key drivers, including the rising prevalence of autoimmune diseases, increasing organ transplantation procedures worldwide, and growing awareness of immunosuppressive therapies among healthcare professionals and patients. The expanding geriatric population, which is more susceptible to autoimmune conditions and organ failure requiring transplantation, significantly contributes to market growth, alongside advancements in transplant surgery techniques and improved patient survival rates that drive sustained demand for long-term immunosuppressive therapy. Additionally, the increasing incidence of chronic diseases such as diabetes and cardiovascular disorders, which often necessitate organ transplantation, further fuels market expansion. However, the market faces substantial restraints including the availability of alternative immunosuppressive agents with potentially superior safety profiles, stringent regulatory requirements for drug approval and monitoring, and the high cost of cyclosporine therapy that may limit accessibility in emerging markets. The drug's narrow therapeutic window and requirement for frequent therapeutic drug monitoring create additional challenges for healthcare providers and patients, while potential side effects including nephrotoxicity, hepatotoxicity, and increased infection risk may limit its use in certain patient populations. Nevertheless, significant opportunities emerge from the development of novel cyclosporine formulations with improved bioavailability and reduced side effects, expansion into emerging markets with growing healthcare infrastructure, and potential applications in treating rare autoimmune conditions. The increasing focus on personalized medicine and pharmacogenomics presents opportunities for optimized cyclosporine dosing strategies, while ongoing research into combination therapies and new therapeutic indications continues to expand the market's potential scope and clinical utility.
Key Features of the Study:
- This report provides in-depth analysis of the global cyclosporine drug market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global cyclosporine drug market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Novartis AG, Teva Pharmaceutical, Sun Pharmaceuticals, Mylan (Viatris), Hikma Pharmaceuticals, Glenmark Pharmaceuticals, Zydus Lifesciences, Lupin Limited, Cipla Ltd, Santen Pharmaceutical, Amneal Pharmaceuticals, Endo International, Strides Pharma, ans Panacea Biotec.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global cyclosporine drug market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global cyclosporine drug market
Market Segmentation
- Application Insights (Revenue, USD Bn, 2020 - 2032)
- Organ Transplant Rejection Prophylaxis
- Kidney Transplant
- Liver Transplant
- Heart Transplant
- Lung Transplant
- Autoimmune Disorders
- Rheumatoid Arthritis
- Psoriasis
- Myasthenia Gravis
- Crohn's Disease
- Nephrotic Syndrome
- Ophthalmic Disorders
- Dry Eye Disease
- Vernal Keratoconjunctivitis
- Dermatological Disorders
- Severe Atopic Dermatitis
- Other Severe Inflammatory Skin Conditions
- Other Uses
- Formulation Insights (Revenue, USD Bn, 2020 - 2032)
- Capsules
- Tablets
- Oral Solution
- Intravenous Solution
- Topical Solution
- Eye Drops
- Type Insights (Revenue, USD Bn, 2020 - 2032)
- Brand
- Generic
- Gender Insights (Revenue, USD Bn, 2020 - 2032)
- Male
- Female
- Age Group Insights (Revenue, USD Bn, 2020 - 2032)
- Pediatric
- Adult
- Geriatric
- End User Insights (Revenue, USD Bn, 2020 - 2032)
- Hospitals
- Specialty Clinics
- Ambulatory Surgical Centers or Transplant Centers
- Homecare Settings
- Academic & Research Institutions
- Others (Specialty Pharmacies)
- Regional Insights (Revenue, USD Bn, 2020 - 2032)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Novartis AG
- Teva Pharmaceutical
- Sun Pharmaceuticals
- Mylan (Viatris)
- Hikma Pharmaceuticals
- Glenmark Pharmaceuticals
- Zydus Lifesciences
- Lupin Limited
- Cipla Ltd
- Santen Pharmaceutical
- Amneal Pharmaceuticals
- Endo International
- Strides Pharma
- Panacea Biotec
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Cyclosporine Drug Market, By Application
- Global Cyclosporine Drug Market, By Formulation
- Global Cyclosporine Drug Market, By Type
- Global Cyclosporine Drug Market, By Gender
- Global Cyclosporine Drug Market, By Age Group
- Global Cyclosporine Drug Market, By End User
- Global Cyclosporine Drug Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Driver
- Restraint
- Opportunity
- Impact Analysis
- Key Developments
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
- Industry Trends
4. Global Cyclosporine Drug Market, By Application, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Organ Transplant Rejection Prophylaxis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Kidney Transplant
- Liver Transplant
- Heart Transplant
- Lung Transplant
- Autoimmune Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Rheumatoid Arthritis
- Psoriasis
- Myasthenia Gravis
- Crohn's Disease
- Nephrotic Syndrome
- Ophthalmic Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Dry Eye Disease
- Vernal Keratoconjunctivitis
- Dermatological Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Severe Atopic Dermatitis
- Other Severe Inflammatory Skin Conditions
- Other Uses
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
5. Global Cyclosporine Drug Market, By Formulation, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Capsules
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Tablets
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Oral Solution
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Intravenous Solution
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Topical Solution
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Eye Drops
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
6. Global Cyclosporine Drug Market, By Type, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Brand
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Generic
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
7. Global Cyclosporine Drug Market, By Gender, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Male
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Female
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
8. Global Cyclosporine Drug Market, By Age Group, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Pediatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Adult
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Geriatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
9. Global Cyclosporine Drug Market, By End User, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Specialty Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Ambulatory Surgical Centers or Transplant Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Homecare Settings
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Academic & Research Institutions
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Others (Specialty Pharmacies)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
10. Global Cyclosporine Drug Market, By Region, 2020 - 2032, Value (USD Bn)
- Introduction
- Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Formulation, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Formulation, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Formulation, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Formulation, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Formulation, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Formulation, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Bn)
- South Africa
- North Africa
- Central Africa
11. Competitive Landscape
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Teva Pharmaceutical
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sun Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Mylan (Viatris)
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Hikma Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Glenmark Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Zydus Lifesciences
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Lupin Limited
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Cipla Ltd
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Santen Pharmaceutical
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Amneal Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Endo International
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Strides Pharma
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Panacea Biotec
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
12. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
13. References and Research Methodology
- References
- Research Methodology
- About us
